CODIT™: Our investigational approach to treating food allergies

Developing a standardized approach to oral immunotherapy to treat food allergies, starting with peanut allergy.

Research suggests that patients with food allergies can be desensitized to exposure to food allergens by ingesting controlled, increasing amounts of the allergen over a period of time. Known as oral immunotherapy (OIT) for food allergy, the approach has been explored by physicians and researchers for more than a century.

Building on this legacy of OIT research, Aimmune’s investigational CODIT approach (Characterized Oral Desensitization Immunotherapy) is now being developed as a standardized approach to treat food allergies, starting with peanut allergy. CODIT is being developed with three key elements:

  • A standardized OIT protocol with precise oral dosing
  • Characterized pharmaceutical products
  • Training and education

We plan to use our investigational CODIT approach with additional development programs for other food allergies beyond peanut.

Using our investigational CODIT approach and associated pharmaceutical products, we seek to help food-allergic individuals reduce the risk of life-threatening reactions due to accidental exposure to food allergens.


The CODIT Approach

Our investigational CODIT approach is based on precise, incremental dosing of a characterized food allergen to achieve gradual desensitization, followed by a daily maintenance dose. The aim of CODIT is to provide an approach for predictable, reliable implementation of OIT that meets the requirements for regulatory approval.

With our investigational CODIT approach, initial administration of a particular dose of food allergen would be done in an allergist’s office, and subsequent administrations would be done at home until the next up-dosing in the allergist’s office. Once desensitized, patients would take a daily maintenance dose to maintain desensitization, and would continue to avoid exposure to their food allergens and carry epinephrine auto-injectors.